Pfizer shutters CovX research operation in San Diego

Pfizer ($PFE) is closing its CovX R&D operation in San Diego a little more than four years after buying the biotech company. About 100 jobs will be lost in the shudown. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.